ALK+ International

New @US_FDA approval for #ros1 #lungcancer #taletrectinib based on TRUST-II looks promising clinical data and great to have more drugs in this area @LungCancer_Bio @LungAssociation @OncoAlert @ros1cancer @ros1dersuk @ALKpositiveINT @ALKPositiveinc fda.gov/drugs/resource…

@urvashi01 You are not alone 💙🩵🩷 #TogetherWeCan further ALK+ research

Three years ago today, I had absolutely no idea what had just hit me. Stage 4 ALK Positive Lung Cancer at just 35 years of age? What on earth was that? Even now, I’m not sure I have better answers. I’ve learned to navigate this so-called “new normal,” but let’s be honest—it’s anything but normal. And I will never get used to it. In the cancer community, we often mark our ‘cancerversaries’. Not because they’re something to celebrate really, but because they are a moment to acknowledge the fire we’ve walked through—another year of surviving, enduring, and fighting the unimaginable. Yes, I’m still here. Not because it’s been easy, but because survival often isn’t a choice—it’s just what we do. Antidepressants have helped me cope, my mother’s relentless determination (and defiance of all odds) has kept me going, and research has quite literally kept me alive. But the reality is terrifying: global funding cuts threaten the very studies that people like me rely on, and here in India, there’s virtually no research dedicated to my type of cancer. So, while I appreciate your kind words, I don’t need to be told I’m an inspiration or that I’m brave—I already know that. What I need—what we all need—is action. Not empty words, not fleeting sympathy. Real, tangible action. Cancer isn’t just a statistic. It’s in our homes, our families, our lives. And if we don’t fight for more research, more funding, and more urgency, the reality is undeniable: it will keep tearing through more lives, more households, until we have nowhere left to turn. We don’t have time for complacency. We don’t have time for ignorance. The situation is dire, and it’s only going to get much worse unless we demand better. Special mention for my doctor @docrohatgi. Meeting an oncologist is never on anyone’s wish list but he’s one I don’t mind meeting now, especially if it’s outside his clinic 😊 #Cancerversary #CancerResearch #Advocacy #ALKPositive #FightCancer #ourlivesmatter @ALKPositiveinc @ALKpositiveINT @IndiaAlk @R2SurviveCancer @VivekSharmaSE @ThanksCancer @YoungLungCancer @theNCI @MDAndersonNews @SU2C @AmericanCancer @nuvalent @MoHFW_INDIA @AyushmanNHA @JPNadda @PMOIndia @PfizerOncMed @ICMRDELHI @CSIR_IND @Roche

ALK+ International is proud to introduce it's new weekly lottery! 🎰 @ALKpositiveINT receives 40% of ticket price regardless of winner status so why not give it a try today and be in to win up to £25,000! 💸👛💸 givinglottery.org.uk/support/alk-in… #Action4Alk #TogetherWeCan

ALK+ International needs you to invest in hope today and donate to vital medical research into ALK+ cancer. Like, share and follow us across all social media platforms to show your support 💙🩵🩷 Whatever you do, big or small makes a difference, join us and take #ACTION4ALK

ALK+ International are now signed up to Recycle4charity! ♻️🦑 Recycle4Charity is a free programme for empty ink cartridges!- help the environment whilst raising money for much-needed research into ALK+ cancer! Donations of up to £2 per ink cartridge recycle4charity.co.uk/register/C1605…

MARIPOSA shows a 25% OS benefit for amivantamab + lazertinib vs osimertinib in newly diagnosed EGFR+ advanced #lungcancer. A big moment—but not a simple one. Side effects, IV treatment & QoL all matter. And right now, this option isn’t available for those in our UK EGFR+ community. Full results Weds at #ELCC25 #LCSM prnewswire.com/news-releases/…

A Journey of Hope: Norman Ng’s Inspiring Story In this episode of OncoInfluencers, @JArakelyan28092 interviews lung cancer survivor Norman Ng, who shares his journey with stage 4 lung cancer, his advocacy work, and his efforts in advancing ALK inhibitors in Hong Kong while emphasizing early detection and patient support. oncodaily.com/dialogues/2512… #PatientSupport #LungCancer #LCSM #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

@weldeiry One of my first papers now cited >100x was on EML4-ALK published in Cancer Biology and Therapy as cover image/story thanks to you @weldeiry tandfonline.com/doi/full/10.41… @BobTimmermanMD @IyengarPuneeth @UTSW_RadOnc @MDAndersonNews

Dr. Edward Garon discusses the circumstances that might lead him to switch a patient with ALK+ NSCLC from another ALK inhibitor to lorlatinib. #NSCLC cancernetwork.com/view/evaluatin…

The review's deep dive into ALK's oncogenic role and emerging resistance to inhibitors is a call to action for innovative cancer therapies. As a cardiologist, I champion the need for sustained research investment, crucial for advancing patient care amidst the UK's challenging funding landscape.

Ultra-deep sequencing of high-risk neuroblastomas found oncogenic aberrations are more prevalent at diagnosis than once thought. ALK and RAS pathway aberrations confer inferior outcomes, emphasizing the need for novel therapeutic approaches. ascopost.com/news/march-202…

ALK+ International is looking for Volunteers! Passionate about ALK+ cancer research? Social media experience? Want to get involved with advocacy? If you believe that research saves lives come and join our team and help us further ALK+ cancer research. #Action4Alk #TogetherWeCan

Cascade-responsive nano-PROTACs for tumor-specific ALK protein degradation and enhanced cancer therapy sciencedirect.com/science/articl…

Now Dr. @jennifermarksmd presenting Biomarker Testing 101 for Lung Cancer at our Targeted Therapies in Lung Cancer. What is a #biomarker? #ALk #ROS1 #LungCancer #TargetedTherapies #cancerGRACE #CancerEducation

Dr. @DrKarenYunMD presenting: How Do You Read a Molecular Testing Report? What are Driver Alterations in Lung Cancer? #TargetedTherapiesInLungCancer #LungCancer #ALK #ROS1 #RET #NTRK #EGFR #BRAF #MET #HER2 #KRAS

We at @cancerGRACE are fortunate to have @ChristineBestv1 from @UCCancerCenter speaking on ALK, ROS1, and RET at our Targeted Therapies forum. She has become deservedly recognized for her thoughtful commentary in many areas of lung cancer. Many options to consider here.

ALK-EML4 fusion in small cell lung cancer: Clinical and molecular insights from a rare case - Lung Cancer @LungCaJournal lungcancerjournal.info/article/S0169-…

🎙 NEW PODCAST EPISODE! The Riddle Of Drug Response. Today, we speak with Dr. Zachary Rogers, a post-doctoral researcher at MIT’s Koch Institute, whose work on ALK mutations illuminates these advancements. Listen: upstagelungcancer.org/podcasts & on all podcast platforms! #Lilly #Bayer

#MoreResearchMoreLife #ResearchSavesLives  #StrongerTogether #ALKCancer #ALKPositive #LungCancer #Stage4 #LCAM

💙Alternatively you can generate free donations via EasyFundraising, Buy2Give, GiveAsYouLive, etc.  🩷Making a donation is easy through Facebook or Instagram using the Meta platform. You can also donate via Paypal, JustGiving or our preferred charity platform Kindlink,

There is still lots of time to donate and invest in hope for a better future for ALK+ cancer patients.  Ways to donate:  🩵Leave a legacy in your will 💙Add gift aid to your donation  🩷Create a monthly direct debit  🩵Talk to your employer and add payroll giving